Background {#Sec1}
==========

The anti EGFR-antibodies cetuximab and panitumumab represent well-established treatments for metastatic colorectal cancer (CRC), the third most prevalent cancer entity and fourth most common cause of cancer-related death around the world \[[@CR1], [@CR2]\]. Several studies have shown *KRAS* status to predict outcome under these anti-EGFR targeting agents, with beneficial effects being seen only in patients whose tumors express wildtype (WT) *KRAS* \[[@CR3]--[@CR8]\]. Thus, testing for *KRAS* mutations, which are found in approximately 40 % of colorectal cancers, has become routine in the management of metastatic CRC (mCRC) prior to cetuximab or panitumumab treatment \[[@CR9], [@CR10]\] and is even required by the responsible regulatory agencies. Notably, current standards regarding oncogenic Ras mutation analysis in mCRC issued by the U.S Food and Drug Administration (FDA) require determination of *KRAS* status by an FDA-approved test, while the European Medical Agency (EMA) just states application of validated methods by an experienced laboratory \[[@CR11]--[@CR15]\]. Currently available FDA-approved companion diagnostic devices for cetuximab (Erbitux) and panitumumab (Vectibix) comprise the Cobas *KRAS* Mutation Test (Roche) and *Therascreen KRAS* RGQ PCR Kit (Qiagen) \[[@CR16]\]. Besides these and other commercially available kits, the spectrum of methods for *KRAS* mutation testing encompasses multiple PCR-derived and sequencing-based techniques. Of note, most of the previously established assays for *KRAS* mutation detection focus on the hotspot mutations involving codons 12 and 13, which account for \>95 % of Ras mutations in CRC \[[@CR10]\]. The advantages and limitations of selected methods have been repeatedly evaluated comparatively \[[@CR17]--[@CR22]\], however, beyond the FDA-guideline, there is no consensus on the preferred approach to investigate *KRAS* status in routine molecular pathological diagnostics \[[@CR23]\]. Given the high incidence of CRC resulting in high demand for *KRAS* mutation testing, an ideal diagnostic assay for this purpose not only needs to be sufficiently sensitive and specific, but, for socio-economic reasons, also should be time- and cost-effective. Therefore, we developed a two-step procedure for *KRAS* mutation testing including high resolution melting analysis (HRM) followed by pyrosequencing of only those samples that are not clearly identified as *KRAS* WT or mutant by HRM. HRM is a one-tube qPCR-based technique for DNA-variant detection. The method utilizes alterations in the melting behavior of double-stranded DNA fragments that are conferred by nucleotide exchanges. Melting of qPCR amplicons is monitored in real time using a suitable qPCR instrument capable of time-dense data aquisition and a saturating DNA-intercalating fluorescent dye that does not redistribute during the melting step \[[@CR24]\]. Pyrosequencing is a sequencing-by-synthesis approach that involves sequential addition of dNTPs and recording incorporation of a nucleotide based on a light signal that is generated by sulfurylase-catalyzed conversion of the released pyrophosphate to ATP and a subsequent luciferase reaction \[[@CR25]\]. Here, we applied a previously described HRM-assay \[[@CR20]\] and the *Therascreen KRAS* Pyro kit (Qiagen) for detection of *KRAS* codon 12/13 mutations. First we comparatively analysed *KRAS* status in a panel of 61 colon cancer samples to determine sensitivity, specificity, technical performance and concordance of results of the two methods. Subsequently, we evaluated our two-step approach in the routine setting of our molecular diagnostics laboratory. In summary, we present a reliable, time- and cost-effective operational concept for *KRAS* mutation testing prior to anti-EGFR antibody treatment in mCRC.

Methods {#Sec2}
=======

Tumor samples, control cell lines and DNA isolation {#Sec3}
---------------------------------------------------

The colorectal cancer samples reported on in this study were obtained from patients with metastatic colorectal cancer (UICC IV) at the University Hospital Marburg, Germany and analysed in a routine diagnostic setting. Tissue samples were fixed, paraffin-embedded, sectioned, hematoxylin-eosin stained and deparaffinated using standard procedures. Tissue sections were reviewed by an experienced pathologist (RM) to establish the diagnosis and to mark regions for microdissections. Microdissection of tumor cells was performed from deparaffinated sections using a scalpel. DNA was isolated from microdissected samples using the QiaAmp DNA Mini kit (Qiagen) as recommended by the manufacturer. *KRAS* mutant cell lines PL45 (pancreatic adenocarcinoma) and RPMI 8226 (multiple myeloma) were obtained from ATCC and cultured according to standard cell culture methods. Positive control DNA for HRM analyses was isolated from these cell lines using the QiaAmp DNA Mini kit. WT control DNA was extracted from peripheral blood of healthy donors from whom informed consent had been obtained (WT control) with the QiaAmp DNA Mini kit. DNA concentrations were measured using a Nanodrop 1000 spectrophotometer (Peqlab).

High resolution melting analysis {#Sec4}
--------------------------------

For HRM analysis, a 92 bp amplicon spanning exons 2 and 3 of the *KRAS* gene was amplified from 60 ng (or less) of sample DNA using the primers *KRAS*-92_F 5′-ttataaggcctgctgaaaatgactgaa-3′ and *KRAS*-92_R 5′-tgaattagctgtatcgtcaaggcact-3′ \[[@CR20]\], the DNA-intercalating dye SYTO 9 (Thermo) in a final concentration of 5 μM and Platinum Taq polymerase (Thermo). Amplification and melting analysis was performed on a Rotor Gene 6000 instrument (Corbett Life Sciences) under the following temperature conditions: one cycle 95 °C/2 min, 40 cycles 95 °C/15 sec -- 67.5 °C/15 sec - 72 °C/15 sec, one cycle 95 °C/1 sec, pre-melt conditioning at 72 °C/90 sec, HRM-ramp from 72 °C to 95 °C rising at 0.2 °C per step/wait 2 sec each step. Controls in each HRM run included a no-template-control, a WT control (gDNA from healthy donor) and two mutation controls (gDNA from the cell lines RPMI 8226, *KRAS* codon 12 GGT → GCT/heterozygous, corresponding to G12A and PL45, *KRAS* codon 12 GGT → GAT/heterozygous, corresponding to G12D). All HRM assays were performed in quadruplicate.

Pyrosequencing {#Sec5}
--------------

Pyrosequencing of the *KRAS* codon 12/13 region was performed using the *Therascreen KRAS* Pyro Kit (Qiagen) as recommended by the manufacturer. 2 ng of DNA were used per analysis. PCR amplification of the target region was performed on a T-100 thermocycler (Biorad). For the pyrosequencing reaction on the PyroMark Q24 platform (Qiagen), amplicons were immobilized to the wells of a PyroMark Q24 plate using streptavidin high performance beads (GE Healthcare). Pyrosequencing results were analysed using the PyroMark Q24 software version 2.0 with the *Therascreen* KRAS Pyro-plugin report, which already incorporated the thresholds for mutation calls (detection limit for the mutation (LOD) + 3 %).

Statistical analysis {#Sec6}
--------------------

HRM and pyrosequencing results were compared by contingency table analysis test using GraphPad Prism 5 software (GraphPad). Technical performance (1st run success vs. 1st run failure) was evaluated by two-sided Fisher's exact test at a significance level of 5 %. The agreement between HRM and pyrosequencing results was quantified by kappa using the appropriate Graphpad Prism online calculator (<http://graphpad.com/quickcalcs/kappa2>).

Results {#Sec7}
=======

Sensitivity of HRM and pyrosequencing {#Sec8}
-------------------------------------

In order to test whether pyrosequencing allows for *KRAS* mutation detection with at least equal sensitivity compared to HRM, we analysed serial dilutions of DNA from a *KRAS* mutant cell line (PL45, codon 12 GGT → GAT heterozygous mutation) in WT DNA by both HRM and pyrosequencing. For HRM, we found, that the presence of *KRAS* mutant DNA in the sample was clearly reflected by a shifted or skewed melting curve for a fraction of PL45-DNA exceeding 25 %, which corresponded to a mutant allele frequency of 12.5 % (Fig. [1](#Fig1){ref-type="fig"}). Similarly, pyrosequencing definitely yielded a mutation if the sample contained ≥25 % PL45-DNA. On the other hand, samples with 5--10 % cell line DNA were indicated to exhibit a potential low level mutation as the mutant allele frequency was quantified below the threshold for accurate WT/mutant discrimination for the G12D mutation (LOD + 3 %; LOD = 2,2 %) for both the 5 and 10 % samples (Fig. [2](#Fig2){ref-type="fig"}). Thus, HRM and pyrosequencing appeared to be equally sensitive methods for the detection of KRAS codon 12/13 mutations.Fig. 1Sensitivity of HRM. Dilutions of genomic DNA from the *KRAS* mutant cell line PL45 (codon 12 GGT → GAT, heterozygous mutation) in WT genomic DNA was analysed by HRM. Normalised fluorescence and difference graphs are indicated. Clear discrimination of WT and mutant amplicons is possible using either graph if the fraction of PL45-DNA in the sample exceeds 25 %, corresponding to a mutant allele frequency of 12.5 %Fig. 2Sensitivity of pyrosequencing. Dilutions of genomic DNA from the *KRAS* mutant cell line PL45 (codon 12 GGT → GAT, heterozygous mutation) in WT genomic DNA was analysed by pyrosequencing on the Pyromark Q24 platform. The WT sequence and the sequence to analyse including wobble bases at the potentially mutant positions in the region of interest (codons 12 and 13) are indicated in the top panel. Lower panels: KRAS codon 12/13 pyrograms for different dilutions of PL45-DNA in WT DNA. Clear mutation calls are obtained for samples containing ≥25 % of PL45-DNA, corresponding to 12.5 % mutant alleles. For lower concentrations, yielding signals below the LOD of the mutation (2.2 %) + 3 %, presence of a potential low level mutation is suggested, which requires technical and/or biological replication of the analysis

Technical reliability of HRM and pyrosequencing {#Sec9}
-----------------------------------------------

To further assess the suitability of pyrosequencing to serve as a backup-assay allowing for accurate diagnosis of *KRAS* mutation status in case of failed HRM analysis, we investigated *KRAS* status of 61 colorectal cancer samples by both HRM and pyrosequencing and compared the two methods with regard to their technical performance and concordance of results. In a first run of HRM analysis, 11/61 samples (18.0 %) could not be analysed due to PCR-failures or ambiguous melting curves (Table [1](#Tab1){ref-type="table"}). Repetition of the assay for seven samples, which most likely had been compromised technically, allowed for assigning *KRAS* mutation status in all cases. The remaining four samples were directly subjected to pyrosequencing without a second round of HRM analysis. Indeed, *KRAS* status could each be determined, although one sample yielded a potential low level mutation. Of the 57 samples that could be definitely classified as *KRAS* WT or mutant by HRM, 26 WT samples (45.6 % of all samples/68.4 % of WT samples) yielded skewed HRM curves, which, however, did not prevent establishment of a diagnosis (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Moreover, we noted that low DNA content of the samples below the detection limit of the Nanodrop spectrophotometer not necessarily prevented successful HRM analysis. In contrast to HRM, the pyrosequencing assay had to be repeated for only one sample (Table [1](#Tab1){ref-type="table"}). Thus, the failure rate of a first analysis run as a consequence of technical and/or sample-issues was significantly higher for HRM analysis than for pyrosequencing (*p* = 0.0042). Together, pyrosequencing is technically more reliable than HRM due to lower input requirements and a lower incidence of invalid results.Table 1*KRAS* codon 12/13 status by HRM and pyrosequencing in 61 CRC samplesHRMPyrosequencingRun 1Run 2SamplecDNA \[ng/μl\]Run 1Run 2Result% mut. AllelesResult% mut. AllelesFinal result111failedWT ^a^WTWT231WT ^a^WTWT310WT ^a^G12C13.4mut493WT ^a^WTWT526WT ^a^WTWT627WT ^a^WTWT710WT ^a^WTWT843mutG13D73.9mut985failedWTWTWT10N/AmutG13D44.3mut11N/AfailedG12V2.6WT ^b^12N/AWTWTWT13N/AmutG12V41.9mut14126mutfailedG12D65.7mut15133mutG12D74.1mut1697mutG13D52.8mut1747failedWTWTWT1814failedWTWTWT1944WT ^a^WTWT2020failedWT ^a^WTWT21N/AfailedWTWT22138mutG12V12.9mut23325mutG12D56.1mut24140WT ^a^WTWT257mutG12C61.2mut264WT ^a^WTWT2727WT ^a^WTWT2813WT ^a^WTWT29207mutG12D54.5mut3010failedWTG12V1.5WT ^b^3154WT ^a^WTWT32120mutG12V29.2mut3333failedmutG12C33.5mut34N/AmutG12C71.4mut35N/AWTWTWT36N/AfailedWTWT3767WT ^a^WTWT38137mutG12C76.7mut3963mutG12A56mut4013WT ^a^WTWT41113WT ^a^WTWT4282mutG12C75.4mut4339WTWTWT447WT ^a^G12S2WT ^b^4523WT ^a^WTWT4624failed^a^G13D3.5WT ^b^479WT ^a^WTWT4834WT ^a^G12S2WT ^b^4925WT ^a^WTWT5017WTWTWT515WT ^a^WTWT5229WT ^a^WTWT5331mutG12D71.3mut5468WTWTWT5593mutG12D74.2mut56221WTWTWT5783WTWTWT58N/AWT ^a^G12V1.2WT ^b^5935mutG12D83.3mut60N/AWTWTWT6137WT ^a^WTWT^a^Skewed HRM curve^b^LOD/threshold for potential low level mutation (cf. *Therascreen* KRAS Pyro Kit handbook version 1, July 2011): G12D 2.2 %/5.2 %, G12V 1.0 %/4.0 %, G12C 2.1 %/5.1 %, G12S 1.9 %/4.9 %, G13D 1.9 %/4.9 %Table 2Comparison of HRM and pyrosequencing results in 61 CRC samplesRun 1Run 2SummarySummary of ResultsHRMn%n%n% Number of samples61100.07100.0 (11.5)61100.0 Analysis passed5082.07100.05793.4  WT (total)3264.0685.73866.7  WT (skewed HRM curve)2475.0233.32668.4  Mutant (total)1836.0114.31933.3  Mutant (skewed HRM curve)000 Analysis failed1118.00Pyrosequencingn%n%n% Number of samples61100.01100.0 (1.6)61100.0 Analysis passed6098.41100.061100.0  WT (total)4168.304167.2  WT (call: WT)3558.335  WT (call: potential low level mutation)610.006  Mutant1931.71100.02032.8 Analysis failed11.60Concordance of ResultsHRMPyrosequencingn%n% Number of samples5710057100 WT (total)3866.73764.9  WT (call: WT)3357.9  WT (call: potential low level mutation)47.0 Mutant1933.32035.1 Concordant5698.2 Discordant11.8 Correctly classified WT3797.4 Incorrectly classified WT12.6 Correctly classified mutant19100 Incorrectly classified mutant00

Concordance of HRM and pyrosequencing results {#Sec10}
---------------------------------------------

In order to evaluate the diagnostic validity of HRM analysis as a basic test for *KRAS* mutation detection, we compared the results from this assay to pyrosequencing in the 57 samples that could be successfully analysed by both methods. *KRAS* status was assigned concordantly for 56 samples (98.2 %; kappa = 0.961), while the result for one sample with a low mutant allele frequency of 13.4 % (\#3, Table [1](#Tab1){ref-type="table"}) was inconsistent between HRM and pyrosequencing (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Importantly, pyrosequencing indicated the presence of potential low level mutations (mutant allele frequency \< 4.0--5.2 %, cf. Table [1](#Tab1){ref-type="table"}) in four samples that were called WT by HRM. Given that this output is generated due to low signal strength for the potential mutation near the technical detection limit of the pyrosequencing method we finally classified these samples as WT. Conversely, all 19 samples that were clearly identified as mutant by HRM were classified identically by pyrosequencing. Therefore, defining pyrosequencing as the reference method, the specificity of HRM for detection of mutant *KRAS* alleles was 100 %. On the other hand, the specificity for the detection of WT alleles was slightly reduced (97.4 %) due to erroneous interpretation of the HRM curve for the one sample mentioned (\#3, Table [1](#Tab1){ref-type="table"}) with a mutant allele frequency only slightly above the sensitivity threshold of the method. When we applied a different HRM assay for the detection of NRAS codon 61 mutations on an independent set of 19 CRC samples, we found a 100 % concordance of results with reports from a reference laboratory (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Of note, sensitivity of the *NRAS* HRM assay was comparable to the *KRAS* assay and allowed for reliable identification of mutations at a mutant sample fraction of 20 % (Additional file [2](#MOESM2){ref-type="media"}: Figure S1). Taken together, these findings indicate that HRM represents a very reliable basic method for *KRAS* mutation testing.

Two-step *KRAS* mutation testing in routine diagnostics {#Sec11}
-------------------------------------------------------

To evaluate the actual effectiveness of our two-step analysis platform (Fig. [3](#Fig3){ref-type="fig"}) in a routine diagnostic setting, we reviewed effort and outcome of *KRAS* codon 12/13 mutation testing in 120 independent colorectal cancer samples that were examined consecutively in our laboratory according to this concept (Table [3](#Tab3){ref-type="table"}). We found, that *KRAS* status could be determined for 87.5 % of samples by HRM and for 99.2 % of samples in total, when pyrosequencing was applied to samples that could not be successfully analysed by HRM (Table [4](#Tab4){ref-type="table"}). However, for both HRM and pyrosequencing, the failure rate was slightly higher than anticipated based on the observations from our initial 61 sample set (Tables [2](#Tab2){ref-type="table"} and [4](#Tab4){ref-type="table"}). Also of note, the number of samples that were subjected to pyrosequencing in routine diagnostics exceeded the previously estimated need of this analysis (19/120 = 15.5 % vs. 4/61 = 6.6 %) because 15 samples were directly analysed by pyrosequencing after the first failed HRM run in order to utilize otherwise wasted capacities. Yet, in summary, these data strongly support the rationale of our two-step approach to *KRAS* codon 12/13 mutation analysis, confirming the accuracy of our diagnostic platform.Fig. 3Outline of the two-step procedure for *KRAS* codon 12/13 mutation analysis. Genomic DNA from microdissected colorectal cancer cells from FFPE samples is subjected to HRM of a PCR amplicon spanning the mutation-bearing region of interest. For samples that are clearly identified as *KRAS* mutant or, respectively, WT, the HRM result is incorporated in the final diagnostic report. Samples for which HRM analysis fails technically or which yield ambiguous HRM curves are further evaluated by a second round of HRM and, if results are still invalid, to pyrosequencing. Note that samples for which a WT result is obtained by the diagnostic procedure outlined here require further examination for additional *KRAS* and *NRAS* mutationsTable 3Detailed results of *KRAS* codon 12/13 mutation testing in 120 CRC samplesHRMPyrosequencingRun 1Run 2Samplec~DNA~ \[ng/μl\]Run 1Run 2Result% mut. AllelesResult% mut. AllelesFinal result62541WT ^a^WTWT6329WT ^a^WTWT64378WTWT65342WT ^a^WTWT66176failedWT ^a^G12V3.2G12V5.2WT67139mutmut68520WTWT6942WTWT70202WTWT71157mutmut72259mutmut73145WTWT7421failedfailedWTWT7522failedWTWT7666mutmut7755mutmut78199mutmut79197WTWT80171WTWT8155failedG12V41.1mut82231failedWTWT83250failedWTWT8457failedWT ^a^WT8521mutmut86248WTWT87258WTWT8883failedfailedfailedN/A8938failedWTWT90279WTWT91122failedWTWT92129failedLow Mut.5.2Low Mut.8.2mut9358WTWT94129WTWT95254WTWT96373WTWT97158WTWT9896mutmut9922WTWT10030mutmut10126mut^a^mut^a^G13D7.3mut10249WTWT10347WTWT10443WTWT10554WTWT106363failedmutmut107521failedWTWT108199mutmut109260WTWT11067WTWT111103WTWT11224mutmut113150WTWT1145WTWT11525WTWT11633WTWT11726mutmut11872WTWT11916failedG12V12.8mut12033failedWTWT12148WTWT12274WTWT123474mutmut124431mutmut12566mutmut126143mutmut12749failedWTWT128143WTWT129122mutmut130139WTWT13121failedWTWT13239failedWTWT133128failedG12D26.7mut13460mutmut135330failedmutmut136165mutmut137213mutmut13831failedmutmut139156mutmut14059WTWT14168WTWT142164WTWT143238mutmut14412mutmut14533failedWTWT14681WTWT14711WTWT14813mutmut14971WTWT15011mutmut15140failedWTWT15250WTWT153128mutmut154146WTWT15569WTWT156182WTWT15732failedWTWT158142WTWT15953WTWT16091failedWTWT161334WTWT16286failedWTWT16361WTWT16464WTWT165141WTWT166271WTWT16740WTWT16834failedWTWT16929failedfailedWTWT170354WTWT17166WTWT17243failedWTWT173114WTWT174268WTWT175107WTWT176170mutmut17765failedmutmut17831failedmutmut17961WTWT180659mutmut18134WTWT^a^Skewed HRM curveTable 4Operational analysis of two-step *KRAS* mutation testing of 120 CRC samplesRun 1Run 2SummaryHRMn%n%n% Number of samples120100.020100.0 (16.7)120100.0 Analysis passed8974.21890.010587.5  WT (total)6067.41266.77167.6  WT (skewed HRM curve)35.0216.745.6  Mutant (total)2932.6633.33432.4  Mutant (skewed HRM curve)13.4116.712.9 Analysis failed3125.8210.0Pyrosequencingn%n%n% Number of samples19100.0 (15.8)3100.0 (2.5)19100.0 Analysis passed1894.7266.71894.7  WT1266.700.01372.2  Potential low level mutation211.1150.000.0  Mutant422.2150.0527.8 Analysis failed15.3133.31Combined HRM + Pyrosequencingn% Number of samples120100.0 Number of HRM runs140116.7 Number of pyrosequencing runs2218.3 Analysis passed11999.2 WT8168.1 Mutant3831.9 Analysis failed10.8

Assay costs {#Sec12}
-----------

In order to estimate the economic benefits of our two-step approach to *KRAS* mutation testing, we compared analysis costs in our routine setting to a pyrosequencing-only platform. Based on current list prices for reagents and consumables, we estimated the assay costs for HRM analysis and pyrosequencing at approximately € 7.50 and € 100, respectively (Table [5](#Tab5){ref-type="table"}). The costs for the essential technical devices for both methods have not been converted to per-sample costs because operation expenses are highly dependent on sample throughput, including not only the *KRAS* mutation assay but also other applications. Moreover, investments for technical equipment are in the same range for pyrosequencing and HRM. Considering the failure rates of each assay in our set of 120 routine samples (23.6 % for HRM and 9.1 % for pyrosequencing), leading to repeated testing of some samples, our two-step approach allows for net reduction of operational costs of approximately 75 % compared to pyrosequencing alone. Moreover, according to our experience, hands-on time for processing the maximum number of samples for one HRM-run (14 + 4 controls) is only half of the time required to prepare and perform a pyrosequencing run at full capacity (22 + 2 controls) (Table [5](#Tab5){ref-type="table"}). Therefore, our concept to maintain two sequential assays for *KRAS* codon 12/13 mutation testing represents cost- and time-effective approach for routine diagnostics.Table 5Per-sample costs and hands-on time for HRM and pyrosequencing analysesHRMPyrosequencingCosts (Euro) Reagents3.4090.00 Consumables2.403.50 Controls1.708.50 Total7.50102.00Time (minutes) 14 samples + 4 controls60 22 samples + 2 controls120Costs for the controls were estimated based on the maximum number of samples that can be processed in one HRM- or pyrosequencing run, respectively. Costs for HRM controls also include DNA isolation from *KRAS* WT and mutant cell lines. Hands-on time is indicated for full capacity runs

Discussion {#Sec13}
==========

Here we present a two-step approach to *KRAS* codon 12/13 mutation testing for mCRC employing HRM analysis and pyrosequencing using the *Therascreeen KRAS* Pyro Kit. Comparing the performance of the two methods in a panel of 61 samples, we observed a 98.2 % concordance of results with a 100 % specificity of HRM for the detection of mutant alleles. Thus, HRM analysis needs methodically independent confirmation of results by pyrosequencing only in exceptional cases and therefore can serve as a filter assay to exclude clearly WT or mutant samples from the more expensive and more laborious pyrosequencing analysis. Specifically, based on our observations reported here, this approach can reduce throughput of the pyrosequencing assay by \>85 %, resulting in a \>75 % cost reduction compared to using pyrosequencing only. We emphasize, that our comparison of the two methods in the first place aimed on diagnostic accuracy for sequential application in order to establish a reliable and economized platform for *KRAS* mutation testing. Of note, we reached this goal in spite we were able to detect mutant *KRAS* alleles only at a frequency \>12.5 % instead of 5 % as reported in the literature \[[@CR20], [@CR26]\].

With respect to technical performance, although we successfully applied HRM to very low input samples, we state a clear advantage for the pyrosequencing assay due to lower input requirements and an apparently relatively high susceptibility of HRM to artifacts. More precisely, previous authors have pointed out, that especially WT HRM curves show a certain degree of variation resulting from poor quality of FFPE-derived template DNA, differing salt- or inhibitor concentrations or unspecific amplification \[[@CR20], [@CR27]\], that may complicate correct determination of *KRAS* status. Consistent with this notion, 6 of the 7 samples in our 61-sample validation set that were subjected to a second round of HRM analysis due to poor interpretability of first round results were eventually called WT by this method. Conversely, we did not obtain false positive results by HRM, i.e., none of our samples that had been identified as mutant by HRM was found to be WT according to pyrosequencing. Yet, we state that the mutation frequency of *KRAS* codon 12/13 observed in our study was slightly lower than reported in the literature \[[@CR9], [@CR10]\], which may be explained by our homogenous patient population from a single center (Marburg, Germany).

Concerning diagnostic value of results from our sequential *KRAS* mutation analysis procedure, it is important to point out that pyrosequencing results include information on the site, type and frequency of the nucleotide exchange, while HRM only allows for categorical discrimination of WT and mutant tumors. According to current standards, such a dual output is actually sufficient to establish the indication for anti-EGFR treatment, although certain authors have suggested that not all *KRAS* mutations are equal regarding outcome in mCRC patients treated with cetuximab \[[@CR3]\]. Consequently, as clinical routine testing at present in principle does not require sequence-based analysis, the more differentiated output of the pyrosequencing assay does not warrant the higher costs for this analysis. Therefore, the two-step procedure for *KRAS* mutation testing presented here represents a reasonable diagnostic approach not only from a technical-practical and economical, but also from a clinical perspective. More specifically, using our diagnostic platform focused on *KRAS* codon 12/13 mutation testing, even small diagnostic laboratories can provide accurate and clinically meaningful results within a short processing time for the most relevant genetic alteration that determines a treatment decision for mCRC patients. Consequently, only a small fraction of patient samples has to be sent to an external reference laboratory for further molecular studies in accordance with the current EMA standards and recommendations by the American Society of Clinical Oncology, which state that Ras mutation testing prior to initiation of treatment with cetuximab and panitumumab has to include analysis of both *KRAS* and *NRAS* exons 2, 3 and 4 (codons 12, 13, 59, 61, 117 and 146). Also of note, besides *KRAS* and *NRAS* mutations, alterations in several other genes such as *BRAF* and *PIK3CA* have been proposed to predict outcome with EGFR antibody treatment \[[@CR28]--[@CR30]\]. Thus, identification of patients eligible for cetuximab or panitumumab treatment in fact requires either a broad panel of single mutation tests or a multiplex approach. Optimized methods for DNA melting analysis of short PCR amplicons have been suggested to allow for comprehensive hot spot mutation testing in a clinical setting as they require only standard qPCR equipment. However, each assay requires careful optimization, implying considerable efforts for a diagnostic laboratory to set up all tests on site \[[@CR31]\]. Alternatively, next generation sequencing (NGS) with a targeted resequencing approach appears to be a suitable technology for extensive clinically relevant mutation testing in the future, which has already been evaluated for the molecular diagnostics of colorectal cancer \[[@CR32], [@CR33]\]. Given the high frequency of *KRAS* codon 12/13 mutations compared to other *KRAS*- or *NRAS* mutations and the fact that these mutations occur mutually exclusive \[[@CR10]\], it still seems reasonable, to filter the samples that actually need advanced testing method as proposed here. Thus, a two-step approach including HRM analysis of *KRAS* codon 12/13 mutations followed by next generation targeted resequencing might be the most attractive implementation for routine *KRAS* mutation diagnostics in the future.

Conclusion {#Sec14}
==========

We present a diagnostically reliable and cost-effective two-step approach to *KRAS* codon 12/13 mutation testing of CRC samples prior to initiation of treatment with anti-EGFR antibodies. The platform appears to be especially attractive for small to medium diagnostic laboratories that don't have the capacities to maintain an extensive spectrum of rare mutation tests according to regulatory standards for diagnostic laboratories \[[@CR34]\] or to adopt NGS-technology with its complex associated infrastructure including bioinformatics.
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